KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) Non Operating Income (2018 - 2025)

Esperion Therapeutics' Non Operating Income history spans 8 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 10.94% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $3.5 million, down 56.49%, while the annual FY2025 figure was $3.5 million, 56.49% down from the prior year.
  • Non Operating Income reached $1.1 million in Q4 2025 per ESPR's latest filing, up from $677000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $3.9 million in Q4 2021 to a low of $9000.0 in Q2 2021.
  • Average Non Operating Income over 5 years is $1.2 million, with a median of $1.1 million recorded in 2023.
  • The largest YoY upside for Non Operating Income was 16312.5% in 2021 against a maximum downside of 96.2% in 2021.
  • A 5-year view of Non Operating Income shows it stood at $3.9 million in 2021, then crashed by 65.6% to $1.4 million in 2022, then dropped by 20.3% to $1.1 million in 2023, then increased by 11.76% to $1.2 million in 2024, then fell by 10.94% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Non Operating Income are $1.1 million (Q4 2025), $677000.0 (Q3 2025), and $666000.0 (Q2 2025).